Psychiatry for Practice, 2006, issue 5

Editorial

Hra, sada, zápas pro Jaroslava Boučka

Mgr. Iva Daňková

Psychiatr. pro Praxi, 2006; 5: 203

Review articles

Antipsychotics treatment and metabolic syndrome

MUDr. Dita Kalnická, prof. MUDr. Jan Libiger CSc

Psychiatr. pro Praxi, 2006; 5: 207-210

Metabolic syndrome (MS) is a complex of metabolic changes that includes abdominal obesity, elevation of blood pressure, impairment of glucose tolerance and lipid changes. The prevalence of MS is higher in patients with schizophrenia than in general population. Its presence may affect the elevated mortality rate among the patients. The interest in the influence of pharmacological treatment on the incidence of metabolic syndrome in patients with schizophrenia appeared after the second generation of antipsychotic drugs had been introduced. The results of studies that investigated the association of the metabolic syndrome with pharmacological treatment...

Osteoporosis and schizophrenia

MUDr. Ivan Tůma CSc

Psychiatr. pro Praxi, 2006; 5: 211-213

Osteoporosis is a multifactorial disease. Untreated patients with schizophrenia are at risk due to the consequences of the disease related lifestyle factors (nutritional alteration, smoking, polydipsia, lack of physical activity). The etiology of the osteoporosis may be partly explained by the prolacting-raising effect of antipsychotic medication. Hyperprolactinemia itself does not lead to osteoporosis. Decrease of bone mineral density associated with schizophrenia may result from hypogonadism secondary to antipsychotic-induced hyperprolactinemia. The most common clinical signs of hypogonadism is dys/amenorrhea, and galactorrhea in female patients,...

The Pharmacotherapy of Depression

doc. MUDr. Ján Praško CSc, MUDr. Hana Prašková

Psychiatr. pro Praxi, 2006; 5: 214-224

The introduction of antidepressants revolutionized not only the treatment of depression but also the way we view the disease itself. In this article, we discuss the treatment of depression, with a focus on proper evaluation, choice of an agent and strategies in the case of resistance to the treatment.

Case report

EFEKTIVITA LÉČBY SCHIZOFRENIE VE SVĚTLE DVOU FÁZÍ STUDIE CATIE

MUDr. Jiří Masopust

Psychiatr. pro Praxi, 2006; 5: 235-240

První zkušenosti u dopravně psychologických, EEG a neurologických vyšetření podle §87a zákona 411/2005

Mgr. et Mgr. Aleš Jelínek, MUDr. Oldřich Vyšata, doc. MUDr. Jiří Hovorka CSc

Psychiatr. pro Praxi, 2006; 5: 247-249

Vnímání léčby sexuálních deviací pracovníky sexuologických a ostatních oddělení psychiatrických léčeben

Bc. Ivana Buříková, prof. MUDr. Alexandra Žourková CSc

Psychiatr. pro Praxi, 2006; 5: 250-253

Věrná společnice

MUDr. Iveta Zedková, MUDr. Zdeněk Faldyna

Psychiatr. pro Praxi, 2006; 5: 254-256

MIRTAZAPIN U MENTÁLNÍ ANOREXIE S KOMORBIDNÍ DEPRESÍ

MUDr. Pavel Theiner Ph.D, MUDr. Markéta Žáčková

Psychiatr. pro Praxi, 2006; 5: 257-258

DIAGNOSTIKA A MOŽNOSTI TERAPIE DEPRESE V POKROČILÝCH STADIÍCH DEMENCE

MUDr. Henrieta Tondlová

Psychiatr. pro Praxi, 2006; 5: 241-242

Psychiatrické příznaky (psychomotorické zpomalení, kognitivní porucha, zmatenost, poruchy chování, delirium, demence, aj.) mohou být způsobeny nekonvulzivním epileptickým statem

doc. MUDr. Jiří Hovorka CSc, MUDr. Michal Bajaček, MUDr. Tomáš Nežádal, MUDr. Markéta Janicadisová, MUDr. Erik Herman

Psychiatr. pro Praxi, 2006; 5: 243-246

Psychopharmacology

USING OF LAMOTRIGINE IN THE TREATMENT OF PSYCHICAL DISORDERS

doc. MUDr. Ján Praško CSc, MUDr. Erik Herman, MUDr. Pavel Doubek, doc. MUDr. Jiří Hovorka CSc, MUDr. Hana Prašková

Psychiatr. pro Praxi, 2006; 5: 229-234

Lamotrigine is an anticonvulsant drug with good efficacy and safety in the treatment of epilepsy. There is now substantial evidence that lamotrigine is also useful in treating bipolar disorder, resistant depression, rapid cycling bipolar disorder and in the maintenance phase or profylaxis of bipolar disorder. Recent reports suggesting that lamotrigine can be also an effective possibility for treatment in borderline personality disorder, a common comorbid personality disorder in bipolar patients, have possible role in reducing chronic pain and treating schizoaffective disorder.